TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06566469
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
Study: NCT04696952
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142
Study: NCT04696952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06259006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules taken orally three times daily for three days
Study: NCT05414734
Drug: HHT120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral administration
Study: NCT05414734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral administration
Study: NCT05661916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection.
Study: NCT06565897
Drug: Test regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste \& manual toothbrush
Study: NCT06565897
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste \& manual toothbrush
Study: NCT05863325
Drug: HB1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
Study: NCT05328531
Drug: Genakumab for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/1ml/bottle
Study: NCT05328531
Drug: Placebo for Genakumab for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
Study: NCT04883333
Drug: LEO 153339
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 153339
Study: NCT04883333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04895358
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04895358
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration
Study: NCT04895358
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05101928
Drug: Ozurdex 0.7mg Ophthalmic Implant
Normalized name: Ozurdex 0.7mg Ophthalmic Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
Study: NCT05970354
Drug: VersaPro Cream Base for Compounding
Normalized name: VersaPro Cream Base for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05145283
Drug: NaCl 0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
Study: NCT06533098
Drug: Intravenous immunoglobulins (IVIG)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG will be administered intravenously.
Study: NCT06254495
Drug: PF-08046044/SGN-35C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenously)
Study: NCT04981613
Drug: Kunxian capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
Study: NCT05391607
Drug: Hyperoncotic Albumin 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Study: NCT05682222
Drug: EDP2939
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP2939 is a pharmaceutical preparation of extracellular vesicles.
Study: NCT05682222
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo.
Study: NCT05140824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution
Study: NCT04937452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for 24 weeks
Study: NCT04265209
Drug: SPECT
Normalized name: Spectrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[123I\]-FP-CIT SPECT imaging procedure
Study: NCT04265209
Drug: PET
Normalized name: PETN
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\] LBT-999 PET imaging procedure
Study: NCT00201552
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06067698
Drug: Mesalamine and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
Study: NCT05831670
Drug: KSP-0243
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05831670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06014515
Drug: 11C-butanol
Normalized name: BUTANOLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
Study: NCT04614233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
Study: NCT06529185
Drug: pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient will receive the usually pharmacological treatment.
Study: NCT05950152
Drug: Meloxicam Injection 30mg
Normalized name: meloxicam Injection
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meloxicam injection 30mg every 24 hours for up to 2 dose
Study: NCT05950152
Drug: Meloxicam Injection 60mg
Normalized name: meloxicam Injection
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meloxicam injection 60mg every 24 hours for up to 2 dose
Study: NCT05950152
Drug: Nacl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo every 24 hours for up to 2 doses
Study: NCT06536023
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 SA.QW
Study: NCT06536023
Drug: IBI362 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 placebo SA.QW
Study: NCT05251779
Drug: Volatile Oil of Cang-Ai
Normalized name: Lantana camara leaf volatile oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
Study: NCT05849922
Drug: SAR442970
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
Study: NCT05849922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL extractable volume of placebo filled in 2 mL glass vial
Study: NCT05601531
Drug: Vit.D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
Study: NCT04955678
Drug: Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
Study: NCT04955678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
Study: NCT04855201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05509192
Drug: Classic Induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
Study: NCT06300307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05504876
Drug: HEC74647PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered HEC74647PA 100 mg orally once daily in fed state;
Study: NCT05504876
Drug: HEC110114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered HEC110114 600 mg orally once daily in fed state;
Study: NCT05630963
Drug: PET radiotracer
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.
Study: NCT04633187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
Study: NCT05610813
Drug: VER-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
Study: NCT05610813
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
Study: NCT05481476
Drug: AG
Normalized name: AGP
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
Study: NCT06023758
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
Study: NCT05738681
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
Study: NCT04874311
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
Study: NCT04608539
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose infusion (placebo), postoperative day 1
Study: NCT06102824
Drug: Organoid-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
Study: NCT06102824
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
Study: NCT06102824
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1250mg/m2, PO, bid, days1-14, q3w
Study: NCT06102824
Drug: Anthracycline
Normalized name: Anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
Study: NCT05898022
Drug: Placebo (plus placebo electrolyte solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
Study: NCT02422368
Drug: Methylprednisolone + ASTED
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Study: NCT02422368
Drug: Methylprednisolone +Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Study: NCT05678998
Drug: WTX-330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigation Product
Study: NCT05997277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of a tablet (0mg) and will be administered orally BID for 16weeks.
Study: NCT06410924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching DD01
Study: NCT06542445
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
Study: NCT05608837
Drug: OCS-01
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
Study: NCT05897424
Drug: SAR447537
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1PI, Recombinant, Bivalent Fc Fusion Protein
Study: NCT04983589
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
Study: NCT05797948
Drug: CD19/CD22 CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
Study: NCT05797948
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 300mg/m2 ivgtt d3-d5.
Study: NCT05838768
Drug: HRO761
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05349760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/D5W
Study: NCT05238701
Drug: LPM3770164 sustained release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
Study: NCT05238701
Drug: LPM3770164 sustained release tablet simulant
Normalized name: STAPHYLOCOCCUS SIMULANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
Study: NCT06316843
Drug: Valacyclovir celecoxib dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg valacyclovir 200 mg celecoxib taken two times a day
Study: NCT06316843
Drug: Valacyclovir celecoxib dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg valacyclovir 200 celecoxib mg taken two times a day
Study: NCT06316843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules colored matched to investigational product taken two times a day
Study: NCT06136624
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally or IM as a rescue medication
Study: NCT06525311
Drug: K-808
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-808 single or multi dose extended-release tablets
Study: NCT04718727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Placebo tablets one-hour preoperatively
Study: NCT06041269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05451849
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT05307198
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
Study: NCT06566352
Drug: injection of epinephrine 1mg diluted in 200mg of NaCl
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of epinephrine 1mg diluted in 200mg of NaCl
Study: NCT05839548
Drug: Mepivacaine 2% with epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Anesthesia
Study: NCT05839548
Drug: Articaine (4%) with epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Anesthesia
Study: NCT06565871
Drug: HRS9531 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration administration, SC
Study: NCT06565871
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC
Study: NCT04785027
Drug: PSORI-CM01 formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
Study: NCT04785027
Drug: Gu Ben Hua Yu formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
Study: NCT05122598
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
Study: NCT00137878
Drug: TNFerade™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04530123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-101 placebo-matching intravenous infusion
Study: NCT04356196
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT05499130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05109416
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic crystaloid
Study: NCT04672954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
Study: NCT04672954
Drug: 2.5 milligram (mg) BI 474121
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
Study: NCT04672954
Drug: 20 milligram (mg) BI 474121
Normalized name: bis-isobutylene PPG-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
Study: NCT04990284
Drug: L-DOPA/DDCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
Study: NCT05260658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTX-1554 matching placebo
Study: NCT05933265
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A competitive mineralocorticoid receptor antagonist that inhibits aldosterone-dependent sodium reabsorption/ potassium excretion and lowering blood pressure, as well as degrades the transcription coupled nucleotide excision repair protein ERCC3 to impair DNA repair.
Study: NCT05195619
Drug: Low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
Study: NCT05008783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
Study: NCT05131893
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy